NEW YORK (GenomeWeb News) – Dako said on Monday that it has entered into an additional collaboration with Amgen to develop a companion diagnostic for an Amgen cancer drug candidate.
Terms of the deal were not disclosed.
The deal builds on an agreement between the two companies announced last month under which Dako is developing a companion diagnostic for a drug from Amgen for an undisclosed rare but deadly cancer.
The company also has similar diagnostic agreements with AstraZeneca, Bristol-Myers Squibb, and Genentech.
"This new collaboration with Amgen underlines Dako's commitment to advance personalized medicine in cancer treatment as the selection of patients most likely to benefit from a specific treatment will increase the probability of therapeutic success for cancer patients," Dako CEO Lars Holmkvist said in a statement.